| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellular Biology |


From the Stem Cell Biology Program (M.K., M.W., J.R., M.Z.R.), the Institute of Molecular Cardiology (B.D., G.H., Y.G., R.B.), and the Institute of Cellular Therapeutics (F.R., S.T.I.), University of Louisville, Louisville, Ken; and the European Stem Cell Therapeutic Excellence Center (M.M.), Cracow, Poland.
Correspondence to Mariusz Z. Ratajczak, MD, PhD, Stem Cell Biology Program, University of Louisville, 580 S Preston St, Baxter II, Rm 119E, Louisville, KY 40202; E-mail mzrata01{at}gwise.louisville.edu; or to Roberto Bolli, MD, Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292. E-mail rbolli{at}louisville.edu
| Abstract |
|---|
|
|
|---|
Key Words: stem cells bone marrow myocardial infarction myocardial regeneration CXCR4-SDF-1 axis
| Introduction |
|---|
|
|
|---|
These uncertainties are part of an ongoing intense debate regarding the mechanism responsible for the functional benefits observed after cellular transplantation. Two basic possibilities have been proposed: cell fusion9,10 and transdifferentiation. In this report, we propose a third possibility, which may reconcile the apparently discordant results obtained by the proponents of cell fusion and transdifferentiation. We have previously demonstrated that the adult murine BM harbors CXCR4+ tissuecommitted stem cells (TCSCs) for various tissues, including skeletal muscle, liver, and neural tissue1113 and have proposed that these TCSCs contribute to the organ/tissue chimerism observed after transplantation of BM- or mobilized peripheral blood (PB)derived cells in earlier reports. In this study, we provide evidence, both in mice and in humans, that the postnatal BM harbors a population of CXCR4+/lin/CD45 nonhematopoietic MNCs that express early markers for cardiac differentiation. These cells are mobilized into the PB following myocardial infarction (MI) and are capable of migrating toward SDF-1, HGF, and LIF gradients. We propose that these cells may potentially be expanded in vitro and used for therapeutic myocardial regeneration.
| Materials and Methods |
|---|
|
|
|---|
Murine and Human Bone Marrow Cells
Murine MNCs were isolated from the BM of 4- to 6-week-old Balb/C mice. Human MNCs were isolated from four cadaveric BM donors (52 to 65 years old) and, if necessary, depleted of adherent cells and T lymphocytes (AT MNC).14,15 Details are provided in the online data supplement available at http://circres.ahajournals.org.
FACS Isolation
Human Cells
CXCR4+/CD45+, CXCR4+/CD45, CXCR4/CD45+, and CXCR4/CD45 BMMNCs were isolated as specified in the online data supplement.
Murine Cells
Lin/Sca-1+/CD45 and Lin/Sca-1+/CD45+ cells were isolated from the suspension of murine BMMNCs as specified in the online data supplement.
Hematopoietic Assays
For cell proliferation assays, murine or human sorted BMMNCs were plated in serum-free methylcellulose cultures.14,15 For the CFU-spleen (CFU-S) assays, colonies were counted on the surface of the spleen using a magnifying glass.14 Specific conditions and methodology are provided in the online data supplement.
Chemotactic Isolation
The method for the chemotactic isolation has been described.11,12 Briefly, cells were resuspended in serum-free medium and equilibrated for 10 minutes at 37°C. The lower chambers of Costar Transwell 24-well plates were filled with 650 µL of serum-free medium and 0.5% BSA containing SDF-1 (200 ng/mL), HGF (10 ng/mL), or LIF (50 ng/mL) or with medium alone (control). Details are provided in the online data supplement. Cells from the lower chambers were collected and their numbers counted by flow cytometry.14,15
Real-Time RT-PCR
Total mRNA was isolated from cells and mRNA was reverse-transcribed with TaqMan Reverse Transcription Reagents. Quantitative assessment of Nkx2.5/Csx, GATA-4, MEF2C, VE-cadherin, and ß-actin mRNA levels was performed by real-time RT-PCR as detailed in the online data supplement. The relative quantitation value of target, normalized to the endogenous control ß-actin (house-keeping) gene and relative to a calibrator, is expressed as 2
Ct (-fold difference), where
Ct=(Ct of target genes)(Ct of endogenous control gene, ß-actin), and 
Ct=(
Ct of samples for target gene)(
Ct of calibrator for the target gene).
Studies of Myocardial Infarction
Two groups (n=24/group) of wild-type mice (B6,129 strain, 8 to 12 weeks old) were used. The experimental preparation has been described in detail.16 Group I underwent a 30-minute coronary occlusion followed by reperfusion, whereas group II underwent a sham operation (1-hour open-chest state).16 Mice (n=6/group at each time-point) were euthanized at 6, 24, 48, or 96 hours after reperfusion, and blood samples as well as myocardial tissue samples from the ischemic and nonischemic regions were harvested.
Immunocytochemistry
The expression of GATA-4 and Nkx2.5/Csx was quantitated by confocal microscopy following immunocytochemistry as detailed in online data supplement.
Statistical Analysis
Data are reported as mean±SD. All statistical analyses were performed using the Instat 1.14 software (GraphPad). Data were analyzed using the Student t test for unpaired samples. Statistical significance was defined as P<0.01.
| Results |
|---|
|
|
|---|
|
|
FACS Isolation of Cells Expressing Early Cardiac Markers
Because cells exhibiting early hematopoietic stem cell markers such as murine Sca-1 and human CD34 and AC133 antigens have been reported to contribute to tissue regeneration,1921 we sought to determine whether these cells correspond to the cells expressing early cardiac markers. We used real-time RT-PCR to compare the expression of mRNA for cardiac markers between different subsets of cells isolated from murine and human BM. We found that FACS-sorted (Figure 3A) murine Sca-1+/lin/CD45 cells were highly enriched (up to 1000x) in mRNA for early myocardial markers (Figure 3B). Immunohistochemical staining (Figure 3C) demonstrated that Sca-1+/lin/CD45 cells (top panel) were smaller than Sca-1+/lin/CD45+ cells (bottom panel) and that
6% of these cells expressed GATA-4 protein. Importantly, in contrast to Sca-1+/lin/CD45+ cells, these cells were not hematopoietic, because they neither grew hematopoietic colonies in in vitro cultures, nor formed day-11 CFU-S colonies in vivo in lethally irradiated littermates (data not shown). Thus, the expression of CD45 is helpful in distinguishing, within the Sca-1+/lin BMMNC population, HSCs (Sca-1+/lin/CD45+) from potential cardiac progenitors (Sca-1+/lin/CD45).
|
As demonstrated in Figure 4, purified CD34+ and AC133+ cells in human BMMNCs were highly enriched (up to 25x) with mRNA for cardiac markers (Nkx2.5/Csx, GATA-4, and MEF2C). As expected,22 these CD34+ and AC133+ cells were also enriched with mRNA for selected endothelial progenitor markers (VE-cadherin, VEGFR3, and vWF). Furthermore, mRNA for early cardiac markers was additionally more enriched in CD45 fraction of purified human CXCR4+, CD34+, and AC133+ cells, and similar to what was observed in mice, appropriate in vitro clonogenic assays confirmed that these cells are nonhematopoietic (data not shown). Together, these data demonstrate that BMMNCs expressing cardiac markers are abundant within a population of nonhematopoietic CXCR4+/Sca-1+/lin/CD45 BMMNCs in mice and within a population of nonhematopoietic CXCR4+/CD34+/AC133+/CD45 BMMNCs in humans.
|
Release of Cells Expressing Early Cardiac Markers Into the PB After Acute MI
Real-time RT-PCR was used to detect the expression of mRNA for cardiac and endothelial markers in PBMNCs collected at specific time-points after MI. Figure 5 demonstrates a marked increase in mRNA content for cardiac (Nkx2.5/Csx, GATA-4, and MEF2C) and endothelial (VE-cadherin) markers in PBMNCs harvested after MI, which peaked at 48 hours after MI and essentially disappeared by 96 hours (Figure 5). Importantly, at 48 hours after MI, the expression of both GATA-4 and Nkx2.5/Csx was detected by immunocytochemistry in
0.1% of the PBMNCs. These cells were not detectable in sham-operated animals (data not shown). These results validate our RT-PCR data at the protein level. Together, these data indicate that cells expressing cardiac markers are released from the BM into the PB in response to myocardial ischemia/reperfusion injury in a manner analogous to what has been described for endothelial progenitor cells23,24
|
Expression of SDF-1, HGF, LIF, and VEGF After Myocardial Infarction
We evaluated the expression of mRNA for SDF-1, HGF, LIF, and VEGF in the LV anterior and posterior walls of mice at 6, 24, 48, and 96 hours after a reperfused MI or a sham operation, respectively. The mRNA for all of these motomorphogens was noted to be maximally upregulated at 48 hours after MI. As demonstrated in Figure 6, 48 hours after a 30-minute coronary occlusion/reperfusion, the expression of SDF-1, HGF, LIF, and VEGF was markedly upregulated in tissue homogenates from the infarcted (LV anterior wall) compared with control (LV posterior wall) myocardium.
|
BM Cells Expressing Early Cardiac Markers Are Chemoattracted to Supernatants From Infarcted Myocardium in an SDF-1, HGF-, and LIF-Dependent Manner
Having found that the supernatant from infarcted myocardium is enriched with mRNA for chemoattractants, we examined whether this supernatant would indeed attract these cells. BMMNCs were allowed to migrate to supernatants from myocardial homogenates obtained from control (posterior wall) and infarcted (anterior wall) myocardial tissue harvested at different time-points after MI. Figure 7A demonstrates that cells expressing early cardiac markers were strongly chemoattracted to supernatants from infarcted myocardium harvested at 48 hours after MI. This chemotactic response could be inhibited by pretreatment of BMMNCs with T140, K-252a compound, or anti-gp190 Ab, known inhibitors of CXCR4, c-Met, and LIF receptors, respectively11,25 (Figure 7B). When combined together, these inhibitors completely blocked the chemotaxis of BMMNCs to the supernatant of infarcted myocardium (Figure 7B). Furthermore, a striking upregulation of mRNA for Nkx2.5/Csx, GATA-4, MEF2C, and VE-cadherin was detected in BMMNCs attracted to supernatant from infarcted myocardium (Figure 7C), indicating that the chemoattracted cells express markers of cardiac (Nkx2.5/Csx+/MEF2C+) and endothelial (VE-cadherin+) progenitors. In contrast, these cells did not express markers for skeletal muscle (MyoD and Myf-5) or neural (nestin and GFAP) TCSCs (Figure 7C).
|
| Discussion |
|---|
|
|
|---|
Salient Findings
The major findings of the present study can be summarized as follows: (1) MNCs expressing mRNA and protein for early cardiac markers are present in postnatal BM in significant amounts and their abundance declines with age; (2) the responsiveness of these cells to chemoattractants changes in an age-dependent fashion; (3) cells expressing early cardiac markers reside in the nonadherent, nonhematopoietic population of CXCR4+/Sca-1+/lin/CD45 BMMNCs in mice and in the population of CXCR4+/CD34+/AC133+/CD45 BMMNCs in humans; (4) these cells are released into the peripheral circulation after MI; and (5) these cells are chemoattracted to homogenates of infarcted myocardium in vitro in an SDF-1-CXCR4, HGF-c-Met, and LIF-LIF-Rdependent manner. To our knowledge, this is the first demonstration that the postnatal BM harbors a nonhematopoietic population of cells that express markers for cardiac differentiation. We propose that these potential cardiac progenitors may account for the myocardial regenerative effects of BM. The present observations have important conceptual implications for our understanding of BM-dependent myocardial regeneration and provide a rationale for further studies aimed at optimizing therapeutic cardiac regeneration by selective use of BM-derived cardiac progenitors.
Postnatal Murine and Human BM Harbors Cells Expressing Early Cardiac Markers
In mice, we found that cells expressing early myocardial markers reside within a population of CXCR4+/Sca-1+/lin/CD45 BMMNCs. The ability of these cells to migrate to HGF and LIF gradients indicates that in addition to CXCR4, these cells also express functional c-Met and LIF receptors. Similarly, in humans, we detected a population of cells expressing cardiac markers within the CXCR4+/CD34+/AC133+/CD45 MNC population. Together, these results suggest that potential cardiac progenitors reside in postnatal BM and constitute a subset of cells that express conventional markers for HSCs (Sca-1 in mice and CD34 and AC133 in humans), an observation that may explain, at least in part, the myocardial regenerative capacity and the functional improvement observed after transplantation of BM- or mobilized PB-derived cells enriched with markers for HSCs (Sca-1+/c-kit+/lin cells).1,26 Furthermore, because CD34 and AC133 in humans and Sca-1 in mice are also expressed in BM-derived endothelial progenitors,2931 our observations may explain the increased vascularization of infarcted myocardium after injection of these cells.1,25 We also found that cells expressing early cardiac markers are enriched with CXCR4+/Sca-1+/CD45 cells that neither grow hematopoietic colonies in vitro nor form CFU-S colonies in lethally irradiated littermates in vivo. In the aggregate, these data demonstrate, for the first time, the existence of cells expressing early cardiac markers in postnatal BM and identify them as a subpopulation of cells distinct from HSCs.
Based on phenotypical analysis, our cells resemble the population of cardiac progenitor cells that was recently isolated from the heart as a "side population" of cardiac cells.32 Similar to our cells, these cells expressed Sca-1 antigen, were CD45 negative, and were found to be distinct from HSCs.32 Interestingly, these cells could also be detected at a very low concentration in PB where 1 cell in 150 000 peripheral blood MNCs displays this phenotype. In this study, we observed a 150-fold enrichment in these cells (1 in 1000 cells) in PB 48 hours after MI. This suggests that potential cardiac progenitors may, as we postulate here, "shuttle" between the BM and the heart and that their number increases during mobilization caused by MI or during pharmacological mobilization by G-CSF.1113
Before concluding that the cells identified in this study are cardiac progenitor cells, it will be necessary to demonstrate that they can regenerate damaged myocardium in vivo. Accordingly, these cells are described in our article as potential cardiac progenitors or cells expressing early cardiac markers. However, we are encouraged by our recent preliminary data showing that these cells can indeed differentiate in vitro into cells that express cardiac-specific markers such as troponin I and cardiac-specific myosin heavy chain (online Figure 1).
BM-Derived Cells Expressing Early Cardiac Markers and Aging
We observed an age-dependent change in the abundance of cells expressing early cardiac markers in murine BM, resulting in barely detectable levels at 1 year of age. These striking differences between old and young animals suggest that these cells are deposited in BM early in ontogenesis during rapid body growth/expansion. We also found that the responsiveness of these cells to SDF-1, HGF, and LIF gradients varies with age: whereas the cells from younger mice responded better to an SDF-1 gradient, the cells from older animals were chemoattracted more efficiently by HGF and LIF. These observations suggest a possible age-dependent phenotypic (density and/or functionality) shift involving the expression patterns of receptors (CXCR4, c-Met, and LIF-R) in these cells. The striking differences in the chemotactic responses of potential cardiac progenitors to these factors have obvious practical implications for BM cellbased therapies.
MI Causes Release of Cells Expressing Early Cardiac Markers That Migrate to SDF-1, HGF, and LIF Gradients
Our data demonstrate for the first time that potential cardiac progenitors are mobilized into the PB after MI, with a peak around 48 hours after MI and a gradual decline to nearly undetectable levels by 96 hours. By immunohistochemical staining, 48 hours after MI
0.1% of PBMNCs were found to express both GATA-4 and Nkx2.5/Csx proteins. In addition, our data demonstrate that the expression of SDF-1, HGF, and LIF increases in infarcted myocardium and that the chemoattraction of BM-derived potential cardiac progenitors to supernatants from infarcted myocardium can be completely abolished by T140, K252a, and anti-gp190, specific inhibitors of CXCR4, c-Met, and LIF-R, respectively, implying that these cytokines play an important role in orchestrating the migration of these cells.
The concept, supported by our findings, that SDF-1 is one of the crucial chemoattractants for recruiting BM-derived cardiac progenitors in ischemic cardiomyopathy is consistent with previous reports.33,34 Our data also point to a potential role of the HGF-c-Met and LIF-LIF-R axes in myocardial regeneration. HGF has been recently shown to increase both proliferation and survival of cardiomyocytes by directly affecting GATA-4 expression.35 Similarly, LIF has been reported to enhance survival of cardiomyocytes and to induce regeneration of myocardium after MI.36
Because these cells reside in the BM, are mobilized into the PB after MI, and can be potentially chemoattracted to injured myocardium in an SDF-1, HGF-, and LIF-dependent manner, the question rises as to why the cardiac regenerative ability of BM-derived cells remains controversial. There are several potential explanations. First, the number of potential cardiac progenitors residing in the BM may be too low and thus insufficient to reconstitute myocardium after the extensive cardiomyocyte loss associated with MI. The primary role of these cells may be to regenerate/repair the relatively small number of cardiomyocytes that die of apoptosis at steady state. Second, circulating cardiac progenitors may have to compete with other CXCR4+ cells (eg, macrophages and lymphocytes) for "homing" into the myocardium and thus may not effectively reach the infarcted region. Finally, in the case of older individuals or individuals experiencing chronic ischemic heart disease, the pool of cardiac progenitors in the BM may become depleted with time, as supported by our present findings.
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
These authors contributed equally to the work. ![]()
This manuscript was sent to Hans Michael Piper, Consulting Editor, for review by expert referees, editorial decision, and final disposition.
Original received July 15, 2004; revision received November 4, 2004; accepted November 4, 2004.
| References |
|---|
|
|
|---|
2. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001; 98: 1034410349.
3. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg. 2002; 73: 19191925.
4. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003; 108: 863868.
5. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002; 106: 19131918.
6. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003; 107: 22942302.
7. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002; 297: 22562259.
8. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell. 2004; 116: 639648.[CrossRef][Medline] [Order article via Infotrieve]
9. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM, Morel L, Petersen BE, Scott EW. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 2002; 416: 542545.[CrossRef][Medline] [Order article via Infotrieve]
10. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, Taneera J, Fleischmann BK, Jacobsen SE. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004; 10: 494501.[CrossRef][Medline] [Order article via Infotrieve]
11. Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J. Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells hide out in the bone marrow. Leukemia. 2004; 18: 2940.[CrossRef][Medline] [Order article via Infotrieve]
12. Kucia M, Ratajczak J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. Blood Cells Mol Dis. 2004; 32: 5257.[CrossRef][Medline] [Order article via Infotrieve]
13. Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek A. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells. 2003; 21: 363371.[CrossRef][Medline] [Order article via Infotrieve]
14. Ratajczak J, Reca R, Kucia M, Majka M, Allendorf DJ, Baran JT, Janowska-Wieczorek A, Wetsel RA, Ross GD, Ratajczak MZ. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood. 2004; 103: 20712078.
15. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, Gewirtz AM, Emerson SG, Ratajczak MZ. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001; 97: 30753085.
16. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol. 1998; 275: H1375H1387.[Medline] [Order article via Infotrieve]
17. Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. Nat Med. 1996; 2: 12811283.[Medline] [Order article via Infotrieve]
18. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science. 2001; 294: 19331936.
19. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001; 105: 369377.[CrossRef][Medline] [Order article via Infotrieve]
20. Korbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002; 346: 738746.
21. Korbling M, Estrov Z. Adult stem cells for tissue repair: a new therapeutic concept? N Engl J Med. 2003; 349: 570582.
22. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000; 105: 1719.[Medline] [Order article via Infotrieve]
23. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001; 103: 27762779.
24. Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol. 2004; 24: 684690.
25. Bailey AS, Jiang S, Afentoulis M, Baumann CI, Schroeder DA, Olson SB, Wong MH, Fleming WH. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood. 2004; 103: 1319.
26. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci. 2001; 938: 221229.[Medline] [Order article via Infotrieve]
27. Forrester JS, Price MJ, Makkar RR. Stem cell repair of infarcted myocardium: an overview for clinicians. Circulation. 2003; 108: 11391145.
28. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428: 664668.[CrossRef][Medline] [Order article via Infotrieve]
29. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964967.
30. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362367.
31. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002; 90: e89e93.[CrossRef][Medline] [Order article via Infotrieve]
32. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003; 100: 1231312318.
33. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003; 362: 697703.[CrossRef][Medline] [Order article via Infotrieve]
34. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation. 2001; 25: 293300.[CrossRef][Medline] [Order article via Infotrieve]
35. Suzuki YJ, Evans T. Regulation of cardiac myocyte apoptosis by the GATA-4 transcription factor. Life Sci. 2004; 74: 18291838.[CrossRef][Medline] [Order article via Infotrieve]
36. Zou Y, Takano H, Mizukami M, Akazawa H, Qin Y, Toko H, Sakamoto M, Minamino T, Nagai T, Komuro I. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation. 2003; 108: 748753.
This article has been cited by other articles:
![]() |
J. L. Herrmann, A. M. Abarbanell, B. R. Weil, Y. Wang, M. Wang, J. Tan, and D. R. Meldrum Cell-based therapy for ischemic heart disease: a clinical update. Ann. Thorac. Surg., November 1, 2009; 88(5): 1714 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Stroo, G. Stokman, G. J. D. Teske, S. Florquin, and J. C. Leemans Haematopoietic stem cell migration to the ischemic damaged kidney is not altered by manipulating the SDF-1/CXCR4-axis Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2082 - 2088. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tendera, W. Wojakowski, W. Ruzyllo, L. Chojnowska, C. Kepka, W. Tracz, P. Musialek, W. Piwowarska, J. Nessler, P. Buszman, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial Eur. Heart J., June 1, 2009; 30(11): 1313 - 1321. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser Bone marrow cell therapy after myocardial infarction. What should we select? Eur. Heart J., June 1, 2009; 30(11): 1310 - 1312. [Full Text] [PDF] |
||||
![]() |
T. Zhao, D. Zhang, R. W. Millard, M. Ashraf, and Y. Wang Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1{alpha} delivery and endogenous cytokine signaling Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H976 - H986. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Paczkowska, M. Kucia, D. Koziarska, M. Halasa, K. Safranow, M. Masiuk, A. Karbicka, M. Nowik, P. Nowacki, M. Z. Ratajczak, et al. Clinical Evidence That Very Small Embryonic-Like Stem Cells Are Mobilized Into Peripheral Blood in Patients After Stroke Stroke, April 1, 2009; 40(4): 1237 - 1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wojakowski, M. Tendera, M. Kucia, E. Zuba-Surma, E. Paczkowska, J. Ciosek, M. Halasa, M. Krol, M. Kazmierski, P. Buszman, et al. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 1 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wojakowski, M. Kucia, K. Milewski, B. Machalinski, M. Halasa, P. Buszman, P. Klimeczek, M. Kazmierski, M. Pasowicz, M. Z. Ratajczak, et al. The role of CXCR4/SDF-1, CD117/SCF, and c-met/HGF chemokine signalling in the mobilization of progenitor cells and the parameters of the left ventricular function, remodelling, and myocardial perfusion following acute myocardial infarction Eur. Heart J. Suppl., December 1, 2008; 10(suppl_K): K16 - K23. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Scobioala, R. Klocke, M. Kuhlmann, W. Tian, L. Hasib, H. Milting, S. Koenig, M. Stelljes, A. El-Banayosy, G. Tenderich, et al. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes FASEB J, April 1, 2008; 22(4): 1021 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Esaki, G. Takemura, K.-i. Kosai, T. Takahashi, S. Miyata, L. Li, K. Goto, R. Maruyama, H. Okada, H. Kanamori, et al. Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1048 - H1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
W Wojakowski, M Kucia, M Kazmierski, M Z Ratajczak, and M Tendera Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart, January 1, 2008; 94(1): 27 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Muller, A. Kazakov, A. Semenov, M. Bohm, and U. Laufs Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells Cardiovasc Res, January 1, 2008; 77(1): 151 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jalili, N. Shirvaikar, S. Ilnitsky, A. R. Turner, M. Z. Ratajczak, and A. Janowska-Wieczorek G-CSF Induces Expression of Both Hepatocyte Growth Factor (HGF) and Its Receptor (c-Met) in Human Hematopoietic Stem/Progenitor Cells and Mature Myeloid Cells - Novel Evidence That during Mobilization the HGF-c-Met Axis Counterbalances G-CSF-Induced Attenuation of the SDF-1-CXCR4 Axis. Blood (ASH Annual Meeting Abstracts), November 16, 2007; 110(11): 2203 - 2203. [Abstract] |
||||
![]() |
Y. Li, P. Atmaca-Sonmez, C. L. Schanie, S. T. Ildstad, H. J. Kaplan, and V. Enzmann Endogenous Bone Marrow Derived Cells Express Retinal Pigment Epithelium Cell Markers and Migrate to Focal Areas of RPE Damage Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4321 - 4327. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Makela, K. Ylitalo, S. Lehtonen, S. Dahlbacka, E. Niemela, K. Kiviluoma, J. Rimpilainen, H. Alaoja, T. Paavonen, P. Lehenkari, et al. Bone marrow derived mononuclear cell transplantation improves myocardial recovery by enhancing cellular recruitment and differentiation at the infarction site J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 565 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Hu, S. Dai, W.-J. Wu, W. Tan, X. Zhu, J. Mu, Y. Guo, R. Bolli, and G. Rokosh Stromal Cell Derived Factor-1{alpha} Confers Protection Against Myocardial Ischemia/Reperfusion Injury: Role of the Cardiac Stromal Cell Derived Factor-1{alpha} CXCR4 Axis Circulation, August 7, 2007; 116(6): 654 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wysoczynski, K. Miekus, K. Jankowski, J. Wanzeck, S. Bertolone, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak Leukemia Inhibitory Factor: A Newly Identified Metastatic Factor in Rhabdomyosarcomas Cancer Res., March 1, 2007; 67(5): 2131 - 2140. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Schatteman, M. Dunnwald, and C. Jiao Biology of bone marrow-derived endothelial cell precursors Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bonaros, R. Rauf, D. Wolf, E. Margreiter, A. Tzankov, B. Schlechta, A. Kocher, H. Ott, T. Schachner, S. Hering, et al. Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1321 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Haudek, Y. Xia, P. Huebener, J. M. Lee, S. Carlson, J. R. Crawford, D. Pilling, R. H. Gomer, J. Trial, N. G. Frangogiannis, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice PNAS, November 28, 2006; 103(48): 18284 - 18289. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, A. Kawamoto, R. Kuroda, M. Ishikawa, Y. Mifune, H. Iwasaki, M. Miwa, M. Horii, S. Hayashi, A. Oyamada, et al. Therapeutic Potential of Vasculogenesis and Osteogenesis Promoted by Peripheral Blood CD34-Positive Cells for Functional Bone Healing Am. J. Pathol., October 1, 2006; 169(4): 1440 - 1457. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dawn, Y. Guo, A. Rezazadeh, Y. Huang, A. B. Stein, G. Hunt, S. Tiwari, J. Varma, Y. Gu, S. D. Prabhu, et al. Postinfarct Cytokine Therapy Regenerates Cardiac Tissue and Improves Left Ventricular Function Circ. Res., April 28, 2006; 98(8): 1098 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, R. G. Reca, P. Atmaca-Sonmez, M. Z. Ratajczak, S. T. Ildstad, H. J. Kaplan, and V. Enzmann Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1646 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Post and J. Waltenberger ACE inhibitors and statins for bone marrow failure following myocardial infarction? Cardiovasc Res, April 1, 2006; 70(1): 1 - 2. [Full Text] [PDF] |
||||
![]() |
H. Iwasaki, A. Kawamoto, M. Ishikawa, A. Oyamada, S. Nakamori, H. Nishimura, K. Sadamoto, M. Horii, T. Matsumoto, S. Murasawa, et al. Dose-Dependent Contribution of CD34-Positive Cell Transplantation to Concurrent Vasculogenesis and Cardiomyogenesis for Functional Regenerative Recovery After Myocardial Infarction Circulation, March 14, 2006; 113(10): 1311 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wojakowski, M. Tendera, A. Zebzda, A. Michalowska, M. Majka, M. Kucia, K. Maslankiewicz, R. Wyderka, M. Krol, A. Ochala, et al. Mobilization of CD34+, CD117+, CXCR4+, c-met+ stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction Eur. Heart J., February 1, 2006; 27(3): 283 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ausoni, T. Zaglia, A. Dedja, R. Di Lisi, M. Seveso, E. Ancona, G. Thiene, E. Cozzi, and S. Schiaffino Host-derived circulating cells do not significantly contribute to cardiac regeneration in heterotopic rat heart transplants Cardiovasc Res, December 1, 2005; 68(3): 394 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dawn and R. Bolli Cardiac Progenitor Cells: The Revolution Continues Circ. Res., November 25, 2005; 97(11): 1080 - 1082. [Full Text] [PDF] |
||||
![]() |
I. Dimarakis, N. A. Habib, and M. Y.A. Gordon Adult bone marrow-derived stem cells and the injured heart: just the beginning? Eur. J. Cardiothorac. Surg., November 1, 2005; 28(5): 665 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bolli, H. Jneid, and B. Dawn Bone Marrow Cell-Mediated Cardiac Regeneration: A Veritable Revolution J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1659 - 1661. [Full Text] [PDF] |
||||
![]() |
S. Erbs, A. Linke, V. Adams, K. Lenk, H. Thiele, K.-W. Diederich, F. Emmrich, R. Kluge, K. Kendziorra, O. Sabri, et al. Transplantation of Blood-Derived Progenitor Cells After Recanalization of Chronic Coronary Artery Occlusion: First Randomized and Placebo-Controlled Study Circ. Res., October 14, 2005; 97(8): 756 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Limana, A. Germani, A. Zacheo, J. Kajstura, A. Di Carlo, G. Borsellino, O. Leoni, R. Palumbo, L. Battistini, R. Rastaldo, et al. Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation Circ. Res., October 14, 2005; 97(8): e73 - e83. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Amado, A. P. Saliaris, K. H. Schuleri, M. St. John, J.-S. Xie, S. Cattaneo, D. J. Durand, T. Fitton, J. Q. Kuang, G. Stewart, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction PNAS, August 9, 2005; 102(32): 11474 - 11479. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wolf, H. Rumpold, E. Gunsilius, W. Wojakowski, M. Tendera, K. Maslankiewicz, R. Wyderka, A. Ochala, A. Michalowska, M. Majka, et al. Response Circulation, May 24, 2005; 111(20): e307 - e308. [Full Text] [PDF] |
||||
![]() |
B. Dawn, A. B. Stein, K. Urbanek, M. Rota, B. Whang, R. Rastaldo, D. Torella, X.-L. Tang, A. Rezazadeh, J. Kajstura, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function PNAS, March 8, 2005; 102(10): 3766 - 3771. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |